|
Index of reports
> Cases with Septic Shock ()
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Vincristine where reactions include septic shock. The selected reports were submitted to the FDA during the sample period of about a year. Reports 1 - 30 of Next >>
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-27
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (4 standard cycles)
Cyclophosphamide
Dosage: 650 mg/m2, day 1 (4 standard cycles)
Cyclophosphamide
Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2, day 1 (4 standard cycles)
Doxorubicin HCL
Dosage: 35 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Etoposide
Dosage: 100 mg/m2, day 1-3 (4 standard cycles)
Etoposide
Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
Indication: Hodgkin's Disease
Prednisolone
Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
Administration route: Oral
Prednisolone
Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
Administration route: Oral
Vincristine
Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, day 8 (4 standard cycles)
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-24
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Doxorubicin Hydrochloride
Dosage: on day 1,for standard cycles
Doxorubicin Hydrochloride
Dosage: for escalated cycles on day 1
Indication: Hodgkin's Disease
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Etoposide
Dosage: for the standard cycles, day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14 every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Vincristine side effects in 18 year old female
Reported by a physician from Slovenia on 2012-08-23
Patient: 18 year old female
Reactions: Pulmonary Haemorrhage, Gastrointestinal Haemorrhage, Injection Site Haemorrhage, Sepsis, Shock Haemorrhagic, Acute Respiratory Distress Syndrome, Bone Marrow Failure, Staphylococcal Bacteraemia, Septic Shock
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Heparin
Vincristine
Dosage: unk
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-08-23
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Septic Shock, Lung Infiltration
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Baxter 15 000 IE Lyofilisat TIL Injeksjonsv?ske / Infusjonsv?s
Cyclophosphamide
Cyclophosphamide
Doxorubicin Hydrochloride
Doxorubicin Hydrochloride
Etoposide
Etoposide
Prednisolone
Administration route: Oral
Procarbazine Hydrochloride
Administration route: Oral
Vincristine
Possible Vincristine side effects in 17 year old male
Reported by a physician from Poland on 2012-08-23
Patient: 17 year old male
Reactions: Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Pyrexia, Renal Failure, Neutropenia, Clostridial Infection, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cefepime
Doxorubicin Hydrochloride
Indication: Ewing's Sarcoma
Etoposide
Indication: Ewing's Sarcoma Metastatic
Ifosfamide
Indication: Ewing's Sarcoma Metastatic
Meropenem
Metronidazole
Netromycin
Vancocin Hydrochloride
Vincristine
Indication: Ewing's Sarcoma Metastatic
Other drugs received by patient: Fluconazole; Caspofungin Acetate
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-08-22
Patient: male, weighing 55.2 kg (121.4 pounds)
Reactions: Unresponsive To Stimuli, Moaning, Neutropenia, Septic Shock, Cardiac Arrest
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Mercaptopurine
Start date: 2009-08-21
Methotrexate Sodium
Prednisone
Vincristine
End date: 2012-08-10
Possible Vincristine side effects in 9 year old male
Reported by a physician from United States on 2012-08-17
Patient: 9 year old male
Reactions: Respiratory Failure, Disseminated Cryptococcosis, Septic Shock
Adverse event resulted in: life threatening event, hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: daily
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Pegaspargase
Dosage: single dose
Indication: Acute Lymphocytic Leukaemia
Vincristine
Dosage: weekly
Indication: Acute Lymphocytic Leukaemia
Possible Vincristine side effects in
Reported by a individual with unspecified qualification from France on 2012-08-15
Patient:
Reactions: Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Cyclophosphamide
Dosage: 3 g/m^2
Cyclophosphamide
Doxorubicin Hydrochloride
Prednisone TAB
Administration route: Oral
Vincristine
Possible Vincristine side effects in female
Reported by a health professional (non-physician/pharmacist) from France on 2012-08-13
Patient: female
Reactions: Septic Shock, Splenic Infarction
Adverse event resulted in: life threatening event
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Nodal Marginal Zone B-Cell Lymphoma
Start date: 2012-06-29
End date: 2012-06-29
Prednisone TAB
Dosage: 1 tablet
Administration route: Oral
Indication: Nodal Marginal Zone B-Cell Lymphoma
Start date: 2012-06-28
Vincristine
Dosage: 1 unit
Indication: Nodal Marginal Zone B-Cell Lymphoma
Start date: 2012-06-29
End date: 2012-06-29
Other drugs received by patient: Aspirin; Acetaminophen; Fasturtec; Pravastatine Arrow; Venlafaxine; Potassium Chloride; Ramipril; Nexium; Bisoprolol Fumarate
Possible Vincristine side effects in 17 year old male
Reported by a physician from Poland on 2012-08-01
Patient: 17 year old male
Reactions: Renal Failure, Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Neutropenia, Clostridial Infection, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Indication: Ewing's Sarcoma
Etoposide
Indication: Ewing's Sarcoma Metastatic
Ifosfamide
Indication: Ewing's Sarcoma Metastatic
Vincristine
Indication: Ewing's Sarcoma Metastatic
Possible Vincristine side effects in 49 year old male
Reported by a health professional (non-physician/pharmacist) from Norway on 2012-07-31
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Lung Infiltration, Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10000 iu
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650mg/m2
Indication: Hodgkin's Disease
Doxorubicin Hydrochloride
Dosage: 25 mg/m2, unk
Indication: Hodgkin's Disease
Etoposide
Dosage: 100 mg/m2, unk
Indication: Hodgkin's Disease
Prednisolone
Dosage: 40 mg/m2
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: 100 mg/m2, unk
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, unk
Indication: Hodgkin's Disease
Possible Vincristine side effects in 17 year old male
Reported by a physician from Poland on 2012-07-27
Patient: 17 year old male
Reactions: Renal Failure, Rhabdomyolysis, Disseminated Intravascular Coagulation, Pancytopenia, Neutropenia, Septic Shock, Clostridial Infection
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Indication: Ewing's Sarcoma
Etoposide
Indication: Ewing's Sarcoma Metastatic
Ifosfamide
Indication: Ewing's Sarcoma Metastatic
Vincristine
Indication: Ewing's Sarcoma Metastatic
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-27
Patient:
Reactions: Anaemia, Skin Toxicity, Febrile Neutropenia, Mucosal Inflammation, Neurotoxicity, Respiratory Failure, Sepsis, Neutropenia, Cardiotoxicity, Septic Shock, Thrombocytopenia, Myocardial Infarction, Diffuse Large B-Cell Lymphoma
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Indication: Diffuse Large B-Cell Lymphoma
Epirubicin Hydrochloride
Indication: Diffuse Large B-Cell Lymphoma
Mabthera
Indication: Diffuse Large B-Cell Lymphoma
Prednisone and Prednisone
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Indication: Diffuse Large B-Cell Lymphoma
Possible Vincristine side effects in 17 year old male
Reported by a health professional (non-physician/pharmacist) from Poland on 2012-07-23
Patient: 17 year old male
Reactions: Abdominal Pain, Rhabdomyolysis, Pain in Extremity, Disseminated Intravascular Coagulation, Chromaturia, Pancytopenia, Pyrexia, Renal Failure, Renal Impairment, Diarrhoea, Clostridial Infection, Septic Shock
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Cefepime
Indication: Pyrexia
Doxorubicin HCL
Indication: Ewing's Sarcoma Metastatic
Etoposide
Indication: Ewing's Sarcoma Metastatic
Ifosfamide
Indication: Ewing's Sarcoma Metastatic
Netilmicin Sulfate
Indication: Pyrexia
Vincristine
Indication: Ewing's Sarcoma Metastatic
Possible Vincristine side effects in
Reported by a physician from Italy on 2012-07-20
Patient:
Reactions: Anaemia, Febrile Neutropenia, Toxicity To Various Agents, Diffuse Large B-Cell Lymphoma Recurrent, Mucosal Inflammation, Neurotoxicity, Sepsis, Adverse Event, Cardiotoxicity, Neutropenia, Thrombocytopenia, Diffuse Large B-Cell Lymphoma, Lymphoma, Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 750 mg/m2 on day 1 for chop and 750 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Doxorubicin HCL
Dosage: 50 mg/m2 on day 1 for chop and 50 mg/m2 on day 2 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Prednisone
Dosage: 100 mg on days 1-5 for chop and r-chop
Administration route: Oral
Indication: Diffuse Large B-Cell Lymphoma
Rituximab
Dosage: 375 mg/m2 on day 1 for r-chop
Indication: Diffuse Large B-Cell Lymphoma
Vincristine
Dosage: 1.4 mg/m2 on day 1 for chop and 1.4 mg/m2 on day 2 for r-chop upto a maximum dose of 2 mg
Indication: Diffuse Large B-Cell Lymphoma
Other drugs received by patient: Neupogen
Possible Vincristine side effects in male
Reported by a physician from United States on 2012-07-16
Patient: male, weighing 27.7 kg (60.9 pounds)
Reactions: Hypotension, Tachycardia, Respiratory Distress, Heart Rate Decreased, Pulmonary Oedema, Septic Shock, Oxygen Saturation Decreased, Pulseless Electrical Activity
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 70 mg
Dexamethasone
Dosage: 78 mg
Methotrexate
Dosage: 15 mg
PEG-L-Asparaginase (Pegaspargase, Oncospar) 2500 IU
Dosage: 2500iu
Vincristine
Dosage: 3 mg
Possible Vincristine side effects in 61 year old male
Reported by a consumer/non-health professional from Germany on 2012-07-13
Patient: 61 year old male
Reactions: Candida Pneumonia, Bronchopneumonia, Febrile Neutropenia, Respiratory Distress, Organising Pneumonia, Respiratory Failure, Interstitial Lung Disease, Pseudomonal Sepsis, Opportunistic Infection, Stenotrophomonas Sepsis, Tracheitis, Septic Shock, Sinusitis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Campath
Dosage: 30 mg, qd
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-08
Campath
Dosage: 30 mg, qd
Start date: 2010-02-22
End date: 2010-02-23
Cyclophosphamide
Dosage: 1380 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Cyclophosphamide
Dosage: 690 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Doxorubicin HCL
Dosage: 92 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Doxorubicin HCL
Dosage: 46 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Pegfilgrastim
Dosage: 6 mg, qd
Start date: 2010-03-01
End date: 2010-03-01
Pegfilgrastim
Dosage: 3 mg, qd
Indication: T-Cell Lymphoma
Posaconazole
Indication: Prophylaxis
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Start date: 2010-02-22
End date: 2010-02-26
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-11
Vincristine
Dosage: 2 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Vincristine
Dosage: 2 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Possible Vincristine side effects in 61 year old male
Reported by a consumer/non-health professional from Germany on 2012-07-10
Patient: 61 year old male
Reactions: Respiratory Failure, Bronchopneumonia, Pseudomonal Sepsis, Febrile Neutropenia, Septic Shock, Tracheitis
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Campath
Dosage: 30 mg, qd
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-08
Campath
Dosage: 30 mg, qd
Start date: 2010-02-22
End date: 2010-02-23
Cyclophosphamide
Dosage: 1380 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Cyclophosphamide
Dosage: 690 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Doxorubicin HCL
Dosage: 46 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Doxorubicin HCL
Dosage: 92 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Pegfilgrastim
Dosage: 3 mg, qd
Indication: T-Cell Lymphoma
Pegfilgrastim
Dosage: 6 mg, qd
Start date: 2010-03-01
End date: 2010-03-01
Posaconazole
Indication: Prophylaxis
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-11
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Start date: 2010-02-22
End date: 2010-02-26
Vincristine
Dosage: 2 mg, unk
Indication: T-Cell Lymphoma
Start date: 2010-01-07
End date: 2010-01-07
Vincristine
Dosage: 2 mg, unk
Start date: 2010-02-22
End date: 2010-02-22
Possible Vincristine side effects in male
Reported by a consumer/non-health professional from Germany on 2012-07-10
Patient: male, weighing 60.0 kg (132.0 pounds)
Reactions: Candida Pneumonia, Bronchopneumonia, Tachycardia, Atrial Fibrillation, Febrile Neutropenia, General Physical Health Deterioration, Lactic Acidosis, Respiratory Distress, Respiratory Failure, Skin Lesion, Pseudomonal Sepsis, Tracheitis, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Campath
Dosage: 30 mg, qd
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-08
Campath
Dosage: 30 mg, qd
Start date: 2010-02-22
End date: 2010-02-23
Cyclophosphamide
Dosage: 690 mg, once
Start date: 2010-02-22
End date: 2010-02-22
Cyclophosphamide
Dosage: 1380 mg, unk
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-07
Doxorubicin HCL
Dosage: 92 mg, unk
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-07
Doxorubicin HCL
Dosage: 46 mg, once
Start date: 2010-02-22
End date: 2010-02-22
Pegfilgrastim
Dosage: 6 mg, once
Start date: 2010-03-01
End date: 2010-03-01
Pegfilgrastim
Dosage: 3 mg, qd
Indication: Peripheral T-Cell Lymphoma Unspecified
Prednisone
Dosage: 100 mg, unk
Administration route: Oral
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-11
Prednisone
Dosage: 100 mg, qdx5
Administration route: Oral
Start date: 2010-02-22
End date: 2010-02-26
Vasopressin
Dosage: unk
Indication: Blood Pressure Management
Vincristine
Dosage: 2 mg, qd
Start date: 2010-02-22
End date: 2010-02-22
Vincristine
Dosage: 2 mg, unk
Indication: Peripheral T-Cell Lymphoma Unspecified
Start date: 2010-01-07
End date: 2010-01-07
Other drugs received by patient: Zienam; Posaconazole; Taranic; Zienam; Taranic; Candiohermal; Candiohermal
Possible Vincristine side effects in 51 year old male
Reported by a physician from Turkey on 2012-06-22
Patient: 51 year old male
Reactions: Drug Ineffective, Pancytopenia, Escherichia Bacteraemia, Disease Progression, Hepatotoxicity, Embolism Venous, Septic Shock, Renal Failure Acute
Drug(s) suspected as cause:
Adriamycin PFS
Indication: Multiple Myeloma
Aspirin
Indication: Thrombosis Prophylaxis
Bortezomib
Indication: Multiple Myeloma
Cyclophosphamide
Indication: Multiple Myeloma
Dexamethasone
Dosage: 40 mg
Administration route: Oral
Indication: Multiple Myeloma
Dexamethasone
Melphalan Hydrochloride
Indication: Bone Marrow Conditioning Regimen
Thalidomide
Dosage: 200 mg
Indication: Multiple Myeloma
Vincristine
Dosage: 0.4 mg
Indication: Multiple Myeloma
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-06-14
Patient: 49 year old male
Reactions: Off Label Use, Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Cyclophosphamide
Doxorubicin HCL
Etoposide
Prednisolone
Administration route: Oral
Procarbazine Hydrochloride
Administration route: Oral
Vincristine
Possible Vincristine side effects in 49 year old male
Reported by a health professional (non-physician/pharmacist) from Norway on 2012-06-11
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on d8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650mg/m2 standard cycles 1250 for the escalated cycles
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 35mg/m2,on d1 for escalated cycles
Indication: Hodgkin's Disease
Etoposide
Dosage: 100mg/m2 for the standard cycles d1 to 3; 200mg/m2 for the escalated cycles from d1-3 iv
Indication: Hodgkin's Disease
Prednisolone
Dosage: on days 1 to 14 in every 21 day cycle treatment for 6 cycles
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day1-7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on d8
Indication: Hodgkin's Disease
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-06-08
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (4 standard cycles)
Bleomycin Sulfate
Dosage: 10000 iu, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 1250 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: 650 mg/m2, day 1 (4 standard cycles)
Doxorubicin HCL
Dosage: 35 mg/m2, day 1 (2 escalated cycles)
Indication: Hodgkin's Disease
Doxorubicin HCL
Dosage: 25 mg/m2, day 1 (4 standard cycles)
Etoposide
Dosage: 200 mg/m2, day 1-3 (2 escalated cycles)
Indication: Hodgkin's Disease
Etoposide
Dosage: 100 mg/m2, day 1-3 (4 standard cycles)
Prednisolone
Dosage: 40 mg/m2, day 1-14 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Prednisolone
Dosage: 40 mg/m2, day 1-14 (4 standard cycles)
Administration route: Oral
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (4 standard cycles)
Administration route: Oral
Procarbazine Hydrochloride
Dosage: 100 mg/m2, day 1-7 (2 escalated cycles)
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, day 8 (2 escalated cycles)
Indication: Hodgkin's Disease
Vincristine
Dosage: 1.4 mg/m2, day 8 (4 standard cycles)
Possible Vincristine side effects in 49 year old male
Reported by a physician from Norway on 2012-06-05
Patient: 49 year old male
Reactions: Pneumocystis Jiroveci Pneumonia, Bone Marrow Failure, Pyrexia, Lung Infiltration, Septic Shock, Infection
Adverse event resulted in: death
Drug(s) suspected as cause:
Bleomycin Sulfate
Dosage: on day 8
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for standard cycles on day 1
Indication: Hodgkin's Disease
Cyclophosphamide
Dosage: for escalated cycles on day 1
Doxorubicin HCL
Dosage: for escalated cycles on day 1
Doxorubicin HCL
Dosage: for standard cycles
Indication: Hodgkin's Disease
Etoposide
Dosage: for the standard cycles, day 1 to 3
Etoposide
Dosage: for the escalated cycles on day 1 to 3
Indication: Hodgkin's Disease
Prednisolone
Dosage: on day 1 to 14
Administration route: Oral
Indication: Hodgkin's Disease
Procarbazine Hydrochloride
Dosage: day 1 to 7
Administration route: Oral
Indication: Hodgkin's Disease
Vincristine
Dosage: on day 8
Indication: Hodgkin's Disease
Possible Vincristine side effects in 49 year old female
Reported by a health professional (non-physician/pharmacist) from Taiwan, Province of China on 2012-05-30
Patient: 49 year old female
Reactions: Multi-Organ Failure, Lymphocytosis, Acute Lymphocytic Leukaemia, Refractory Anaemia, Pneumonia, Septic Shock
Adverse event resulted in: death, life threatening event, hospitalization
Drug(s) suspected as cause:
Cyclophosphamide
Dosage: 100 mg
Administration route: Oral
Indication: Anaemia
Cyclophosphamide
Indication: Breast Cancer
Cyclophosphamide
Indication: Leukocytosis
Start date: 2009-07-01
Cyclophosphamide
Indication: Acute Lymphocytic Leukaemia
Cytarabine
Indication: Acute Lymphocytic Leukaemia
Start date: 2009-07-01
Dexamethasone
Indication: Acute Lymphocytic Leukaemia
Start date: 2009-07-01
Doxorubicin HCL
Indication: Acute Lymphocytic Leukaemia
Start date: 2009-07-01
Epirubicin
Indication: Breast Cancer
Fluorouracil
Indication: Breast Cancer
Methotrexate
Indication: Acute Lymphocytic Leukaemia
Start date: 2009-07-01
Prednisolone
Indication: Leukocytosis
Prednisolone
Dosage: 15 mg
Indication: Anaemia
Vincristine
Indication: Acute Lymphocytic Leukaemia
Start date: 2009-07-01
Possible Vincristine side effects in female
Reported by a individual with unspecified qualification from United States on 2012-05-25
Patient: female, weighing 14.9 kg (32.8 pounds)
Reactions: Anaemia, Hyponatraemia, Rash, Pyrexia, Ascites, Abdominal Pain Upper, Abdominal Compartment Syndrome, Respiratory Failure, Pneumonia Herpes Viral, Bone Marrow Failure, Neutropenia, Thrombocytopenia, Cardiac Arrest, Septic Shock, Infection in AN Immunocompromised Host
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Dexamethasone
Dosage: 17.5 ml
Mercaptopurine
Dosage: 460 mg
Methotrexate
Dosage: 24.5 mg
Vincristine
Dosage: .99 mg
Possible Vincristine side effects in
Reported by a physician from United States on 2012-05-21
Patient:
Reactions: Off Label Use, Cholecystitis, Septic Shock
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Sarcoma
Doxorubicin HCL
Indication: Sarcoma
Etoposide
Indication: Sarcoma
Vincristine
Indication: Sarcoma
Possible Vincristine side effects in
Reported by a health professional (non-physician/pharmacist) from France on 2012-05-10
Patient:
Reactions: Septic Shock
Adverse event resulted in: death
Drug(s) suspected as cause:
Cyclophosphamide
Indication: Chronic Lymphocytic Leukaemia
Doxorubicin HCL
Indication: Chronic Lymphocytic Leukaemia
Granulocyte Colony Stimulating Factor
Indication: Chronic Lymphocytic Leukaemia
Prednisone TAB
Administration route: Oral
Indication: Chronic Lymphocytic Leukaemia
Vincristine
Indication: Chronic Lymphocytic Leukaemia
Possible Vincristine side effects in 18 year old male
Reported by a physician from United States on 2012-04-03
Patient: 18 year old male, weighing 126.4 kg (278.1 pounds)
Reactions: White Blood Cell Count Decreased, Abdominal Pain, Metabolic Acidosis, Clostridium Test Positive, Urine Output Decreased, Hypotension, Hyponatraemia, Capillary Leak Syndrome, Platelet Count Decreased, Septic Shock
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Cytarabine
Dosage: 70 mg;x1;inth
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
Doxorubicin HCL
Dosage: 60 mg/m**2;x1;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-02-24
Hydrocortisone
Indication: Acute Lymphocytic Leukaemia
Methotrexate
Dosage: inth
Indication: Acute Lymphocytic Leukaemia
Oncaspar
Dosage: 2500 iu;x1;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Prednisone TAB
Dosage: 20 mg/m**2;qd;po
Administration route: Oral
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-04
Velcade
Dosage: 1.3 mg/m**2; qd; iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Vincristine
Dosage: 1.5 mg/m**2;qd;iv
Indication: Acute Lymphocytic Leukaemia
Start date: 2012-02-24
End date: 2012-03-02
Page 1 Next >>
|
